A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Anti-BCMA bispecific chimeric antigen receptor T cell therapy-Hrain Biotechnology (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
- Sponsors Hrain Biotechnology
- 26 Sep 2023 New trial record